Abemaciclib/Fulvestrant Boosts PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression
The addition of abemaciclib (Verzenio) to fulvestrant (Faslodex) led to a significant improvement in progression-free survival (PFS) vs fulvestrant alone in patients with hormone receptor–positive, HER2-negative advanced breast cancer who had disease …